The Axiom-4 mission is set to make history by carrying Rebecsinib, the first cancer drug with active US FDA Investigational New Drug (IND) status, into space for testing in microgravity. This development marks a major milestone in the advancement of space-based pharmaceutical research.
Rebecsinib Targets a Key Cancer Gene
Developed by Aspera Biomedicines, Rebecsinib specifically targets ADAR1—a gene known to drive cancer cell cloning and immune system evasion. Unlike earlier space missions that focused on unapproved research compounds, Axiom-4 will test a drug already cleared for human clinical trials on Earth.
“This landmark mission will accelerate the development of the first ADAR1-inhibiting cancer stem cell therapy for a wide range of cancers,” said Dr Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute and founder of Aspera Biomedicines.
Microgravity Offers a Fast-Track Research Environment
Microgravity provides a unique environment for cancer research. Tumours in space tend to grow at nearly twice the rate observed on Earth, giving scientists an accelerated model of aggressive cancer behavior. Dr Jamieson observed that mini-tumours doubled in size within 10 days during earlier missions—mimicking real-world cancer progression and producing more timely scientific insights.
Building on Previous Missions
As reported by TOI, Rebecsinib has already undergone preliminary testing during the Axiom-2 and Axiom-3 missions. Now, Axiom-4 will expand this research by generating preclinical data across various tumour types using patient-derived tumour organoids.
Accelerating Drug Discovery for Aggressive Cancers
By replicating rapid disease progression in space, researchers aim to identify more effective drug candidates. This could lead to higher success rates in clinical applications, especially for patients with fast-growing cancers. The mission underscores how space research can transform cancer treatment on Earth through faster, more accurate drug development.